Diabetes Mellitus: Nursing Care Management

What is Diabetes Mellitus?

Diabetes mellitus (DM) is a chronic metabolic disorder defined by hyperglycemia from a problem with insulin secretion, insulin action, or both. Insulin, made by the pancreas, moves glucose into cells for energy. When insulin is absent, insufficient, or ineffective, glucose builds up in the blood and damages organ systems over time.

The burden is large and growing: an estimated 589 million adults worldwide had diabetes in 2024, and Type 2 makes up over 90% of cases. Once mostly an adult disease, it now shows up in children and adolescents. It is a leading driver of blindness, kidney failure, heart disease, stroke, and amputations, and ranks as the 8th leading cause of death in the U.S.

Classification and Types of Diabetes

The two main types are Type 1 (T1DM) and Type 2 (T2DM). Less common forms include genetic defects (Maturity-Onset Diabetes of the Young, or MODY), pancreatic disease, and drug-induced diabetes.

Type 1 diabetes mellitus (T1DM)

An autoimmune disorder: the immune system destroys the insulin-producing beta cells of the pancreas, leaving an absolute insulin deficiency. Onset is often abrupt and usually in childhood or adolescence (formerly "juvenile diabetes" or insulin-dependent diabetes mellitus), though it can appear in adulthood and be misdiagnosed as type 2. Genetic susceptibility plus environmental triggers (certain viral infections) are implicated. There is no known way to prevent T1DM, and lifelong insulin therapy is required for survival.

Type 2 diabetes mellitus (T2DM)

More than 90% of cases globally. The defects are insulin resistance (cells do not use insulin well) plus a relative insulin deficiency (the pancreas cannot keep up). Glucose rises gradually and often goes unnoticed for years. T2DM usually develops in adulthood, but rising obesity has pushed onset into adolescence. Risk factors: obesity, physical inactivity, poor diet, genetics. Management starts with lifestyle change and oral agents, progressing to injectables or insulin over time. Insulin may not be required at diagnosis.

Gestational diabetes mellitus (GDM)

Glucose intolerance first identified in pregnancy, usually the second or third trimester. Placental hormones drive insulin resistance; when insulin production cannot meet demand, hyperglycemia results. GDM usually resolves after childbirth but raises lifetime risk of type 2. Manage with diet, monitoring, and insulin when needed. Postpartum followup is required to reassess glucose regulation.

Maturity-Onset Diabetes of the Young (MODY)

A rare inherited form from a mutation in a single gene affecting insulin production. It usually appears in adolescence or early adulthood and can be mistaken for type 1 or type 2. Unlike type 1, it typically does not need insulin and often responds to oral hypoglycemic agents.

Pancreatogenic Diabetes (Type 3c)

Results from pancreatic damage (chronic pancreatitis, pancreatic cancer, or surgical removal). It impairs both exocrine and endocrine function, so it affects insulin and digestive enzymes. Management includes insulin therapy and enzyme replacement.

Drug- or Chemical-Induced Diabetes

Corticosteroids, antipsychotics, and immunosuppressants can impair insulin action or secretion and cause hyperglycemia. It may be temporary or permanent depending on drug duration and underlying predisposition. Glucose often normalizes if the agent is stopped early.

Prediabetes

Glucose is elevated but not high enough for a diabetes diagnosis. It raises the risk of type 2 and heart disease, and lifestyle change (weight loss, healthy eating, exercise) can reverse or delay it. Diagnostic markers: FPG 100-125 mg/dL, 2h OGTT 140-199 mg/dL, or A1C 5.7-6.4%.

Epidemiology and Global Impact

Both prevalence and incidence are rising.

Global prevalence: As of 2025, roughly 1 in 9 adults worldwide has diabetes. The International Diabetes Federation estimates 589-590 million adults (20-79 years) living with diabetes in 2024, projected to reach 853 million by 2050 if trends hold. The rise is driven mainly by type 2 from aging, urbanization, obesity, sedentary living, and dietary change. Over 80% of adults with diabetes live in low- and middle-income countries, where rapid lifestyle shifts and limited resources strain prevention and care.

U.S. population: In 2021, about 38.4 million Americans (11.6%) had diabetes, of whom 28.5 million were diagnosed and 8.7 million undiagnosed. Nearly one-third of adults aged 65 and older had diabetes. About 1.2 million new cases occur annually. American Indian/Alaska Native and non-Hispanic Black adults carry higher prevalence, reflecting genetic and social determinants of health.

Type 1 and youth-onset type 2: Type 1 is still the predominant form in children and adolescents. In the U.S., about 2 million people have type 1, including 304,000 under age 20. Each year brings roughly 18,000 new pediatric type 1 cases and 5,000 type 2 cases. Youth-onset type 2 is rising fastest among obese teens in minority populations. Globally about 9 million people live with type 1, with growing numbers diagnosed in adults.

Morbidity and mortality: Vascular complications drive premature illness and death. In 2021, diabetes caused an estimated 1.6 million deaths globally; counting related cardiovascular and kidney deaths, the total exceeds 2 million annually. Nearly half of diabetes-related deaths occur before age 70. In the U.S., diabetes was the 8th leading cause of death, implicated in over 103,000 death certificates.

Economic impact: The U.S. spent over $400 billion on diagnosed diabetes by 2022, with diabetic patients incurring more than twice the healthcare costs of non-diabetics. Worldwide spending exceeds $1 trillion annually.

Diabetes-related complications: Diabetes is a leading cause of end-stage renal disease, blindness from retinopathy, and non-traumatic lower-limb amputations. It roughly doubles the risk of heart attack and stroke. Better glucose control, regular screening, and comprehensive care have reduced some complication rates.

Causes and Risk Factors

The exact cause is unknown, but distinct factors drive each type.

Type 1 Diabetes

An autoimmune attack on the insulin-producing pancreatic cells. Contributors:

• Autoimmune reaction. The immune system destroys insulin-producing beta cells, progressively losing insulin and causing hyperglycemia.
• Genetic susceptibility. Markers HLA-DR3 and HLA-DR4 raise risk, though carrying them does not guarantee disease.
• Family history. A first-degree relative with T1DM modestly raises risk.
• Environmental triggers. Viruses such as enteroviruses or Coxsackie B may initiate the autoimmune response; early cow's milk exposure and low vitamin D are under investigation.
• Autoantibodies. Antibodies to islet cells (GAD65, insulin, IA-2) appear before symptoms and support early diagnosis or screening.

Type 2 Diabetes

Strong lifestyle and behavioral component plus genetic predisposition. Core defects are insulin resistance and relative insulin deficiency. Major risk factors:

• Insulin resistance. Muscle, liver, and fat cells respond poorly to insulin, forcing the pancreas to overproduce until glucose rises.
• Beta-cell dysfunction. Beta cells eventually cannot secrete enough insulin to overcome resistance, worsening hyperglycemia. A hallmark of T2DM progression.
• Obesity, especially abdominal. Excess visceral fat disrupts hormone signaling and promotes inflammation, a leading modifiable driver of insulin resistance.
• Sedentary lifestyle. Inactivity lowers insulin sensitivity and adds weight; exercise improves glucose uptake.
• Poor diet. Refined carbohydrates, added sugars, saturated fats, and sugar-sweetened beverages drive insulin resistance, weight gain, and metabolic abnormalities.
• Genetic predisposition. Family history of type 2 significantly raises risk through genes affecting insulin production, fat storage, and glucose metabolism.
• Age and ethnicity. Risk climbs after age 45 as beta-cell function declines and resistance increases, particularly with inactivity or weight gain. African American, Hispanic, and Asian populations are more susceptible.
• History of gestational diabetes or prediabetes. Both signal a predisposition to insulin resistance and later T2DM.
• Other conditions. PCOS and acanthosis nigricans track with insulin resistance; chronic glucocorticoids or some antipsychotics can predispose to type 2.

Gestational Diabetes

Driven by pregnancy hormones that increase insulin resistance. Risk factors:

• Hormonal changes. Human placental lactogen (hPL), estrogen, and cortisol rise in pregnancy and blunt insulin action, raising glucose especially in the second and third trimesters.
• Obesity or overweight. Central adiposity raises resistance; prepregnancy overweight or obesity sharply raises GDM risk.
• Advanced maternal age. Women over age 25-30 carry higher risk from age-related decline in insulin sensitivity.
• PCOS. Insulin resistance and hormonal imbalance raise GDM risk.
• Ethnicity. Hispanic, African American, Native American, South or Southeast Asian, and Pacific Islander women carry higher risk.
• Family history or prior GDM. Both suggest genetic predisposition and higher later T2DM risk.
• Previous macrosomic baby. A prior baby over 4,000 grams (8 lbs. 13 oz.) signals prior unrecognized glucose intolerance.

Pathophysiology

Normal homeostasis: glucose is the body's primary fuel, regulated by insulin. After meals, insulin drives glucose into cells, suppresses hepatic glucose output, and promotes glycogen and fat storage. During fasting, insulin falls and the liver releases or synthesizes glucose to hold a normal fasting level (70-100 mg/dL). Diabetes breaks this balance.

Type 1 Diabetes Pathophysiology

Autoimmune destruction of beta cells produces absolute insulin deficiency. T-lymphocytes, triggered by genetic susceptibility plus environmental factors, progressively destroy beta cells; once 80-90% are lost, the pancreas cannot make enough insulin. Without insulin, glucose cannot enter muscle and fat, so cells starve despite high blood glucose. The body then breaks down fat into free fatty acids, which the liver converts to ketones; excess ketone production overwhelms buffering and causes metabolic acidosis (diabetic ketoacidosis). Once glucose exceeds the renal threshold (~180 mg/dL), the kidneys cannot reabsorb it all, so glucose spills into urine (glycosuria) and pulls water with it, driving polyuria, dehydration, and polydipsia. Osmotic diuresis also wastes sodium and potassium; serum potassium may look normal or high from extracellular shifting while total body stores deplete, threatening muscle and cardiac function. Protein breakdown for gluconeogenesis adds weight loss, weakness, and, in children, impaired growth.

Type 2 Diabetes Pathophysiology

The lead defect is insulin resistance in muscle, fat, and liver, so glucose uptake falls despite insulin being present. To compensate, the pancreas overproduces insulin (hyperinsulinemia), which holds glucose normal for a time but exhausts beta cells and cannot last. Beta-cell function then declines in quantity and timing; the early first-phase insulin release is lost first, and as function deteriorates, glucose runs persistently high. The liver keeps producing glucose even when blood glucose is already high (it fails to sense insulin's signal to suppress gluconeogenesis), worsening fasting hyperglycemia. The incretin effect is blunted: gut hormones GLP-1 and GIP normally boost post-meal insulin, but their response drops and GLP-1 degradation increases, raising postprandial glucose. Insulin resistance in fat raises lipolysis and free fatty acids, which impair insulin signaling, promote inflammation, and add hepatic steatosis. Visceral fat sustains low-grade inflammation (TNF-alpha, IL-6) and oxidative stress that damage beta cells and accelerate progression. Genetic predisposition plus inactivity, poor diet, and obesity complete the picture.

In both types, chronic hyperglycemia damages the eyes, kidneys, nerves, and vessels through advanced glycation end-products and oxidative stress. The hallmark of diabetes is a fasting blood glucose of 126 mg/dL or higher, or any random glucose of 200 mg/dL or higher with symptoms.

Clinical Manifestations

Symptoms come from sustained hyperglycemia and its systemic effects. Type 1 and type 2 overlap, but onset, severity, and associated features differ.

Classic symptoms in both types:

• Polyuria. Glucose spilling into urine (glycosuria) drags water with it, producing large volumes of dilute urine, frequent daytime urination, and nocturia. In children, look for new-onset enuresis (bedwetting).
• Polydipsia. Fluid loss and dehydration trigger constant thirst; patients drink heavily but stay dehydrated.
• Polyphagia. Cells cannot use glucose without insulin, so hunger persists even with adequate intake; weight loss may still occur, especially in type 1.
• Weight loss. Fat and muscle breakdown for fuel causes visible loss despite increased appetite, more common in type 1 and advanced type 2.
• Fatigue and weakness. Glucose-starved cells underproduce energy; dehydration worsens it.
• Blurred vision. Lens swelling causes temporary, fluctuating vision changes that usually improve with glycemic control but can progress to retinopathy.
• Slow-healing wounds and frequent infections. High glucose impairs immunity and perfusion; watch for UTIs and skin infections.
• Peripheral neuropathy. Chronic hyperglycemia damages peripheral nerves, causing tingling, burning, or numbness in the hands and feet, often present at diagnosis in type 2.
• Irritability and mood changes. Poor concentration or behavioral change can signal high glucose.
• No symptoms. Type 2 often develops silently and is found on routine testing or once complications appear, so screen at-risk patients early.

Remember the "3 P's": polyuria, polydipsia, polyphagia. Unexplained weight loss and fatigue point toward type 1; overweight patients with milder symptoms suggest type 2. Any random blood glucose 200 mg/dL or higher with classic symptoms is diagnostic.

Diagnosis and Diagnostic Tests

Catch it early to start treatment and prevent complications. The American Diabetes Association (ADA) criteria below apply to non-pregnant adults with type 1 or type 2.

Fasting Plasma Glucose (FPG): A fasting glucose 126 mg/dL or higher (7.0 mmol/L) on at least two occasions is diagnostic. "Fasting" means no caloric intake for at least 8 hours. Normal is <100 mg/dL; 100-125 is prediabetes; 126 and above is diabetes.

Glycated Hemoglobin (A1C): Reflects average glucose over the past 2-3 months. A1C 6.5% or higher, confirmed on repeat, indicates diabetes; 5.7-6.4% is prediabetes; <5.7% is normal. No fasting required, but it is unreliable with anemia or hemoglobin variants and is not preferred for acute-onset type 1.

Oral Glucose Tolerance Test (OGTT): Measure plasma glucose after an overnight fast, then 2 hours after a 75 g glucose load. A 2-hour value 200 mg/dL or higher indicates diabetes; 140-199 mg/dL is impaired glucose tolerance (prediabetes); <140 is normal. Cumbersome but sensitive, and used for gestational diabetes or borderline results.

Random Plasma Glucose: A random glucose 200 mg/dL or higher with classic symptoms (polyuria, polydipsia, unexplained weight loss) establishes the diagnosis. In a hyperglycemic crisis (DKA or HHS), a single value above this threshold is enough; waiting for a second test could be dangerous.

Nursing note: If an initial diabetic-range result occurs in an asymptomatic patient, repeat the same test on another day to rule out lab error. Two different tests (such as FPG and A1C) both above threshold also confirm the diagnosis. In symptomatic patients, treatment need not wait for confirmation.

Urine testing: A dipstick detects glucose and ketones. Glucosuria indicates blood glucose >180 mg/dL; ketonuria signals fat breakdown, typical in type 1 or poorly controlled type 2. In children, both findings suggest type 1 and demand urgent testing. Urinalysis can also detect microalbuminuria, an early sign of kidney damage.

Antibody tests: Autoantibodies (GAD65, IA-2, ZnT8) distinguish type 1 from type 2 or LADA, especially in adults or atypical cases. C-peptide reflects endogenous insulin: low in type 1, normal in type 2, high in early type 2.

Lipid profile: At diagnosis, especially in type 2, get a full lipid panel. High triglycerides and low HDL are common from insulin resistance and mark cardiovascular risk.

Baseline metabolic tests: Serum electrolytes, BUN, and creatinine assess kidney function and hydration. In DKA or HHS, blood gases and serum osmolality reveal metabolic acidosis (low pH and low bicarbonate) or severe dehydration.

Glycated hemoglobin (HbA1c): A baseline A1C estimates average glucose over the past 2-3 months. An A1C of 10% reflects an average glucose of ~240 mg/dL and helps guide treatment.

Microalbuminuria screening: Screen type 2 patients at diagnosis; in type 1, begin 5 years after diagnosis or at puberty. A urine albumin-to-creatinine ratio >30 mg/g indicates microalbuminuria and may warrant ACE inhibitors.

Dilated eye exam: Screen for retinopathy shortly after a type 2 diagnosis and 3-5 years after a type 1 diagnosis. Dilating the pupils allows close inspection of the retina and vessels.

Comprehensive foot exam: Checks skin, deformities, infection, and circulation through visual inspection, pedal pulse assessment, and sensory testing (monofilament and vibration). Detects risk early and prevents ulcers and amputations.

Monofilament testing: Press a 10-gram monofilament against set points on the sole until it bends. Inability to feel it at one or more sites indicates peripheral neuropathy and higher ulcer risk.

Diagnostic criteria summary (non-pregnant adult, confirmed on a separate day if asymptomatic): FPG 126 mg/dL or higher; 2-hour OGTT 200 mg/dL or higher after a 75 g load; A1C 6.5% or higher (48 mmol/mol); or random plasma glucose 200 mg/dL or higher with classic symptoms or hyperglycemic crisis.

Complications of Diabetes

Diabetes can hit nearly every organ system. Split complications into acute (immediate crises from severe hyper- or hypoglycemia) and chronic (long-term microvascular and macrovascular damage).

Acute Complications

Hypoglycemia (Low Blood Sugar)

The most common acute problem. Blood glucose falls below 70 mg/dL, usually from insulin or sulfonylureas combined with a skipped meal, extra activity, or too much medication. Symptoms: sweating, shakiness, hunger, irritability, confusion; severe cases bring seizures or unconsciousness.

Management: Give 15g of fast-acting carbohydrate (juice or glucose tablets), recheck in 15 minutes, and repeat if still <70 mg/dL. If the patient is unconscious, seizing, or cannot swallow, give glucagon (IM/subcutaneous) or IV dextrose. Monitor glucose frequently and identify contributing factors (missed meals, excess insulin, unexpected activity).

Diabetic Ketoacidosis (DKA)

Mainly type 1. Severe insulin deficiency produces high blood glucose (usually 250-600 mg/dL), ketone production, and metabolic acidosis (blood pH <7.3). Signs: polyuria, polydipsia, nausea, vomiting, abdominal pain, fruity breath, Kussmaul (rapid/deep) breathing, confusion, dehydration.

Management: IV fluids, starting with isotonic saline (0.9% NaCl) and switching to dextrose-containing solutions once glucose drops. Regular IV insulin lowers glucose, halts ketone production, and corrects acidosis under close monitoring. Watch electrolytes, especially potassium: insulin shifts potassium into cells and risks hypokalemia and arrhythmias, so replace it as needed even when initial levels look normal.

Hyperglycemic Hyperosmolar State (HHS)

Mainly older adults with type 2. Blood glucose can exceed 600 mg/dL with little to no ketone production. Expect severe dehydration, altered mental status, confusion, weakness, polyuria, dry mucous membranes, and low blood pressure.

Management: IV fluids rehydrate and restore perfusion. Insulin lowers glucose gradually to avoid rapid shifts. Replace potassium and other electrolytes, which drop with insulin therapy. Treat the trigger (infection, stroke, missed medications).

Infections

Diabetic patients are more prone to UTIs, pneumonia, and skin infections. Give prescribed antibiotics promptly, since infection worsens glycemic control and can trigger DKA or HHS. Monitor glucose closely (infection raises insulin resistance), encourage hydration, teach sick-day management (keep taking insulin even when not eating), and inspect and care for wounds, which heal slowly.

Chronic Complications

Chronic damage builds from prolonged hyperglycemia, hitting small vessels (microvascular), large vessels (macrovascular), and nerves. Good glycemic control sharply reduces risk.

Microvascular Complications

These damage capillaries and typically appear after 5-10 years in type 1, though they may already be present at diagnosis in type 2 from delayed onset.

Diabetic retinopathy: High glucose damages retinal vessels, causing vision changes or blindness. Early non-proliferative signs are microaneurysms and hemorrhages; proliferative disease adds fragile new vessels that bleed or detach the retina. Annual dilated eye exams are essential. Treatments include laser therapy and anti-VEGF injections.

Diabetic nephropathy: High glucose damages the filtration units, producing microalbuminuria and eventually kidney failure. Screen with the urine albumin-to-creatinine ratio. ACE inhibitors or ARBs protect kidney function early.

Diabetic neuropathy: Affects peripheral and autonomic nerves. Peripheral neuropathy brings numbness, tingling, or pain in the feet and undetected injuries. Autonomic neuropathy affects digestion, urination, and sexual function. Assess routinely and teach foot care and injury prevention.

Diabetic foot ulcers and amputations: Result from neuropathy, poor circulation (PAD), and infection risk. Minor wounds go unnoticed and worsen, sometimes to severe infection or amputation. Diabetes is a leading cause of non-traumatic lower-limb amputations. Prevention: daily foot inspection, proper footwear, prompt wound care, and regular professional foot exams.

Macrovascular Complications

These are accelerated atherosclerosis from the metabolic effects of diabetes, compounded by coexisting hypertension and dyslipidemia.

Cardiovascular disease: Diabetes sharply raises the risk of MI and angina, and many diabetics have silent MIs from neuropathy. Control glucose, blood pressure, and cholesterol. The ADA treats diabetes itself as a high-risk cardiovascular condition and recommends lipid-lowering therapy (statins) for most diabetic patients over 40.

Stroke: Atherosclerosis in cerebral arteries raises ischemic stroke risk. Control blood pressure and lipids, stop smoking, and teach the warning signs.

Peripheral arterial disease (PAD): Atherosclerosis in the leg arteries causes claudication and poor wound healing. Combined with neuropathy, it drives foot ulcers and amputations. Assess pulses and circulation and promote vascular care.

Other complications: heart failure (diabetic cardiomyopathy) from chronic poor control; fatty liver disease (NAFLD) with insulin resistance; and pregnancy complications including congenital anomalies and preeclampsia.

Bottom line: glycemic, blood pressure, and lipid control prevent or delay complications. Routine screening, foot care, vaccinations, and patient education matter just as much.

Management of Diabetes

Management is multidisciplinary: medical treatment, lifestyle change, glucose self-monitoring, and regular followup. The goals are to relieve hyperglycemic symptoms, reach near-normal glucose, and prevent complications.

Nutrition (Dietary Management)

Based on the ADA 2024 Standards of Care:

• Individualized meal planning. There is no single "diabetes diet." Match the plan to the patient's culture, preferences, conditions, and goals, and bring in a registered dietitian.
• Nutrient-dense choices. Push whole, minimally processed foods: vegetables, fruits, whole grains, legumes, lean proteins, healthy fats. Fiber improves satiety and cholesterol.
• Carbohydrate management. Tracking carbohydrate intake limits glucose spikes; carb counting and the glycemic index help insulin users and type 1 patients.
• Moderate alcohol. Alcohol can cause delayed hypoglycemia, especially with insulin or sulfonylureas. If consumed, take it with food and limit to 1 drink/day for women and 2 for men.
• Meal timing and consistency. Regular meals steady glucose, especially on insulin or sulfonylureas; skipping meals risks hypoglycemia. Flexible insulin regimens allow timing to follow carb intake.
• Weight management. In type 2, even a modest 5-10% weight loss meaningfully improves control. In type 1, balance insulin with a healthy diet to avoid weight gain or deficits.
• Heart-healthy eating and portion control. Limit saturated fat, trans fat, and excess salt, especially with hypertension or kidney disease. Favor lean proteins (chicken, fish, tofu) and modest healthy fats (olive oil, avocado).
• Avoid sugary drinks and excess sugar. Soda, sweet tea, and juice spike glucose; steer patients to water, unsweetened drinks, or non-nutritive sweeteners (stevia, sucralose), and flag hidden sugars in processed foods.

Nursing tip: Reinforce dietitian guidance and set realistic, incremental goals (water instead of soda, vegetables at each meal, smaller high-carb portions). Respect cultural food preferences so the plan sticks.

Physical Activity

Exercise is a cornerstone in type 2 and beneficial in type 1 (with precautions). It lowers glucose by raising insulin sensitivity and muscle uptake, aids weight management, and improves cardiovascular health.

• Adults (type 1 or 2): at least 150 minutes per week of moderate-intensity aerobic activity (brisk walking, swimming, cycling) across at least 3 days per week, with no more than 2 consecutive days without activity. Add resistance training 2-3 times per week.
• Children and adolescents: at least 60 minutes of physical activity daily, including aerobic and age-appropriate strength or bone-loading activity.

Exercise safety:

1. Check glucose before and after. If too low (<100 mg/dL), give a snack; if too high (>250-300 mg/dL) with ketones, hold exercise to avoid worsening hyperglycemia or ketoacidosis.
2. Avoid peak insulin action. Exercising when insulin peaks (1-2 hours after rapid-acting insulin) raises hypoglycemia risk; time activity when insulin is stable.
3. Stay hydrated. Dehydration impairs glucose control and stresses the kidneys.
4. Carry fast-acting carbohydrates. Glucose tablets, juice, or hard candy for sudden lows.
5. Wear proper footwear and inspect feet. Well-fitting cushioned shoes and clean dry socks cut blister and infection risk, especially with neuropathy.
6. Start slow and progress gradually. Begin with low-impact walking or swimming to adapt safely.
7. Do not exercise if sick or ketotic. Activity while ill, dehydrated, or ketotic worsens hyperglycemia and can cause DKA.
8. Use a partner or tell someone. Ensures help if hypoglycemia or illness strikes.
9. Watch for post-exercise hypoglycemia. Glucose can drop hours later; monitor and snack as needed.
10. Avoid barefoot or high-impact activity. With impaired sensation, these raise wound and fracture risk; always wear protective footwear.

Weight Management

Most useful in overweight or obese type 2 patients:

• A modest 5-7% weight loss meaningfully improves insulin sensitivity, glycemic control, and cardiovascular health.
• Strategies: reduce calories, control portions, increase activity.
• For BMI 35 or higher, bariatric surgery may be considered when lifestyle change alone falls short and can drive remission in many cases.

Nursing tip: Counsel without judgment, assess readiness to change, and refer to weight management programs. GLP-1 receptor agonists are an option for patients needing extra support.

Diabetes Self-Management Education (DSME)

DSME is structured teaching on glucose monitoring, medication, diet, activity, complication prevention, and coping, usually delivered by certified diabetes care and education specialists. The aim is to equip patients to make informed daily decisions.

Self-Monitoring of Blood Glucose (SMBG)

SMBG uses a glucometer and fingerstick. Frequency follows the regimen:

• Intensive insulin (multiple daily injections or pump): before meals, at bedtime, sometimes 2 hours after meals or overnight, totaling 4-6 times per day or more, to adjust doses and avoid lows.
• Oral meds with low hypoglycemia risk (metformin): less often, once daily at varying times or a few times weekly, to track trends.
• Stable type 2 (non-insulin): daily SMBG may be unnecessary if A1C is on target; occasional fasting and post-meal checks gauge food and activity effects.
• Sick days or therapy changes: monitor more often to catch swings early.

Nursing tip: Teach glucometer technique, hand hygiene before fingersticks, and accurate logging. Typical non-pregnant targets are 80-130 mg/dL fasting and under 180 mg/dL post-meal. Review logged data regularly to spot trends and recommend adjustments.

Continuous Glucose Monitoring (CGM)

CGM tracks interstitial glucose with a subcutaneous sensor, updating every 5 to 15 minutes for dynamic trend data. The ADA now recommends CGM for most type 1 patients (and many type 2 on intensive insulin). It shows time-in-range, helps prevent hypoglycemia, and guides insulin adjustment.

Types: real-time CGM (rtCGM) displays live data; retrospective (professional) CGM stores data for later provider review.

Nursing tip: Teach proper use, sensor calibration, troubleshooting, and when to confirm CGM readings with a fingerstick.

Hemoglobin A1C (HbA1c)

A1C is the key marker of long-term control, reflecting average glucose over the past 2-3 months. Test every 3 months after therapy changes or when not at target, and every 6 months when stable and well-controlled.

Target range (general):

• <7% for many non-pregnant adults.
• <6.5% for younger, healthier patients if achievable without hypoglycemia.
• <7.5-8% for older adults or those with comorbidities.

Nursing tip: Teach that A1C reflects the average over 2-3 months, not daily highs and lows. An A1C of 7% corresponds to roughly 154 mg/dL. Use A1C to cross-check SMBG logs when values seem inconsistent and adjust the plan accordingly.

Pharmacologic Management

Insulin Therapy

Insulin is required for survival in type 1 and often eventually needed in type 2 as the disease progresses or during stress (hospitalization, surgery, pregnancy). Modern regimens mimic natural patterns with basal insulin for around-the-clock coverage and bolus insulin for meals. Types are classified by onset and duration:

• Rapid-acting analogues (Insulin lispro [Humalog], Insulin aspart [NovoLog], Insulin glulisine [Apidra]): begin working within 5 to 15 minutes, peak around 1 hour, last about 3 to 5 hours. Given just before meals and used in pumps. They cut delayed-hypoglycemia risk and add meal-timing flexibility. Lispro and aspart are approved for children as young as 2 to 3 years.
• Short-acting (Regular insulin, Humulin R, Novolin R): onset 30 to 60 minutes, peak 2 to 4 hours, lasts 5 to 8 hours. Give about 30 minutes before meals. It is the only insulin that can be given intravenously, making it essential in DKA and HHS. In pediatrics it is an option but largely replaced by rapid-acting analogues.
• Intermediate-acting (NPH, Neutral Protamine Hagedorn, Humulin N, Novolin N): onset 1 to 2 hours, peak around 4 to 12 hours, duration up to 24 hours. Usually given twice daily for basal control. Its pronounced peak and variability raise mid-day and nocturnal hypoglycemia risk if meals are missed. Still common in type 2 regimens and resource-limited settings.
• Long-acting (basal) analogues (Insulin glargine [Lantus U-100, Basaglar; also Toujeo glargine], Insulin detemir [Levemir]): steady levels with minimal peaks. Glargine lasts up to 24 hours and is usually dosed once daily; detemir may need twice-daily dosing. Lower hypoglycemia risk than NPH. Approved for pediatric use around age six and above.
• Ultra-long-acting (Insulin degludec [Tresiba U-100 or U-200], U-300 glargine [Toujeo]): degludec has onset of ~1 hour and lasts 42 hours or more with a very flat profile, allowing flexible injection timing. Degludec is approved for children as young as 1 year and suits variable schedules or a history of nocturnal hypoglycemia.
• Pre-mixed insulins (70/30 [NPH/regular], 75/25 [NPL/lispro]): combine intermediate with rapid- or short-acting in a fixed ratio, given two to three times daily to cover basal and prandial needs. Convenient but require consistent meal timing and allow less dose flexibility. More common in type 2.

Insulin Regimens

1. Basal-bolus (multiple daily injections, MDI): long-acting once or twice daily plus rapid-acting before meals. Mimics normal pancreatic function and allows flexible meal timing; needs frequent monitoring for accurate dosing.
2. Continuous subcutaneous insulin infusion (CSII, insulin pump): delivers rapid-acting insulin continuously (basal) with mealtime boluses. Better control and fewer injections, but requires training and frequent glucose checks.
3. Split-mixed (less common): intermediate-acting (NPH) mixed with short-acting twice daily. Less flexible and less physiologic, used in resource-limited settings; requires consistent meal timing.

For type 2 specifically:

1. Basal insulin only: once-daily long-acting (glargine, detemir) added to oral meds to control fasting glucose. Often the starting point, simple, with low hypoglycemia risk.
2. Basal-bolus: long-acting plus rapid-acting at meals when basal alone no longer holds control. Requires education, meal planning, and frequent checks.
3. Premixed: fixed intermediate plus short- or rapid-acting (70/30) twice daily before breakfast and dinner. Convenient for routine eaters, less flexible, and can cause lows if meals are delayed.

Side Effects of Insulin

• Hypoglycemia. The most common side effect, from too much insulin, skipped or delayed meals, or added activity without a dose change. Symptoms: shakiness, sweating, confusion, and in severe cases loss of consciousness.
• Weight gain. Insulin promotes fat storage; improved control and extra eating to treat lows add weight.
• Lipodystrophy. Repeated injections at one site cause lipohypertrophy (fat lumps) or lipoatrophy (fat loss), which alter absorption and destabilize control. Rotate sites.
• Allergic reactions. Rare with modern insulin; usually local redness, swelling, or itching at the site. Severe reactions are uncommon.
• Edema. Starting insulin can cause mild fluid retention in the hands or feet, usually temporary, but monitor in heart or kidney disease.

Non-Insulin Medications for Type 2

These are the oral hypoglycemic agents (OHAs) and non-insulin injectables. Key categories:

• Metformin. First-line oral drug. Lowers hepatic glucose production and improves insulin sensitivity. No hypoglycemia when used alone but can cause GI upset early. Avoid in severe kidney disease (lactic acidosis risk).
• Sulfonylureas (glipizide, glyburide, glimepiride). Increase pancreatic insulin secretion. Effective but can cause hypoglycemia (especially with skipped meals) and weight gain. Teach meal timing.
• Thiazolidinediones (pioglitazone). Improve insulin sensitivity in muscle and fat; no hypoglycemia alone. Cause weight gain and fluid retention, so not suitable in heart failure. Pioglitazone may help fatty liver disease.
• DPP-4 inhibitors (sitagliptin, linagliptin). Improve post-meal insulin release and reduce glucagon by preserving incretin hormones. Weight-neutral, low hypoglycemia risk; rarely cause pancreatitis or joint pain.
• SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin). Excrete excess glucose in urine and add weight loss, lower blood pressure, and kidney and heart protection. Common side effects: UTIs and genital yeast infections. Stress hydration and hygiene.
• GLP-1 receptor agonists (liraglutide, semaglutide, exenatide). Injectables that raise insulin when needed, slow digestion, reduce appetite, and lower glucagon. Strong A1C and weight reduction. Nausea is common early; avoid with a history of certain thyroid tumors.
• Insulin in type 2. Added when glucose stays uncontrolled on oral or injectable agents, usually starting with basal insulin. Causes weight gain and hypoglycemia, so adjust doses carefully and educate. When insulin is started, some orals continue (metformin, SGLT2/GLP-1) while others are reduced or stopped (sulfonylureas) to avoid redundancy and lows.
• Other agents. Meglitinides (repaglinide): short-acting secretagogues before meals, effective but can cause lows if meals are missed. Alpha-glucosidase inhibitors (acarbose): delay gut carbohydrate absorption; cause bloating and flatulence. Amylin analogs (pramlintide): injectable used with insulin to slow gastric emptying and suppress appetite, helping post-meal glucose but adding injection burden.

Guidelines for selecting type 2 medications:

1. Consider comorbidities. Heart failure or chronic kidney disease: prefer SGLT2 inhibitors (empagliflozin) for proven heart failure and CKD benefit. Atherosclerotic cardiovascular disease (ASCVD) or need for weight loss: prioritize GLP-1 receptor agonists (semaglutide) for cardioprotection and weight reduction.
2. Start with metformin unless contraindicated (advanced kidney disease), then add a second agent based on response, tolerance, and comorbidities.
3. Use combination therapy when needed. Most patients eventually need two or three medications; tailor to lifestyle, comorbidities, hypoglycemia risk, and cost.

Comprehensive Care and Followup

Diabetes care is more than glucose. Manage blood pressure and cholesterol to cut cardiovascular risk. ACE inhibitors or ARBs are common, especially with kidney involvement. Statins control cholesterol, and low-dose aspirin may be considered with existing or high cardiovascular risk. Smoking cessation matters, since smoking sharply raises heart disease, stroke, and amputation risk.

Routine Screenings and Preventive Measures

Annual screening catches complications early: yearly eye exams for retinopathy, annual foot exams (more often if high-risk), and yearly kidney testing (urine albumin and eGFR). Vaccinate: annual influenza, pneumococcal, and hepatitis B if not already immune.

Psychosocial and Emotional Support

Diabetes is mentally demanding. Assess for financial hardship, low health literacy, depression, and lack of social support. Refer to social workers, diabetes educators, or peer groups. Emotional support drives long-term adherence.

Clinical Targets and Individualization

Standard targets: A1C <7%, blood pressure <130/80 mmHg (or <140/90 for some), and LDL cholesterol <70 mg/dL with cardiovascular disease. Personalize them. Older adults with multiple comorbidities may accept a higher A1C (7.5-8%), while patients planning pregnancy may need tighter control (A1C <6.5%).

Sick Day Management

Never stop insulin during illness, especially in type 1, since illness raises glucose even when food intake drops. Check glucose every 4 hours and check ketones if glucose exceeds 240 mg/dL. Push hydration: sugar-free fluids for hyperglycemia, carbohydrate-containing fluids when food intake is limited. Teach when to seek care (persistent vomiting, high fever, ketones not clearing with insulin). Provide a clear written sick-day plan.

Hospitalization and Surgery

Hospital stays often require temporary therapy changes, with insulin used for tighter control and IV insulin infusions during critical illness or surgery. Monitor glucose closely, manage drips, and guide a safe transition back to the home regimen with education.

Diabetes in Pregnancy

Pregnancy demands tight control to protect the fetus. Insulin is preferred, though metformin or glyburide may be used in select cases. Insulin requirements rise during pregnancy; coordinate glucose monitoring, dietary support, and fetal surveillance.

Special Considerations: Pediatric Diabetes

Pediatric care is family-centered. Most pediatric patients have type 1 and are insulin-dependent, though type 2 is rising with childhood obesity.

Diagnosis and early recognition: Young children may not show classic symptoms, so watch for excessive thirst, frequent urination, and fatigue. Any suspicion warrants immediate glucose and ketone testing.

Glucose targets and insulin: For most children the A1C goal is <7.5%, though <7.0% may be ideal if safe. Targets run higher in very young children to prevent hypoglycemia. Children commonly use basal-bolus regimens, often with pumps or CGMs. Know these technologies and teach families.

Nutrition, growth, and education: Meal plans must support normal growth while controlling glucose. Teach carbohydrate counting early for flexible eating with insulin adjustments. Collaborate with dietitians and adjust insulin for activity. Help train teachers, school nurses, and caregivers.

Psychosocial needs: Support the child and family with education, counseling, and diabetes camps or peer groups. Shift care responsibilities gradually as children grow, and support adolescents struggling with adherence.

Preventing complications and transition: Complication screening (eyes, kidneys) usually begins at puberty or after a few years; for type 2 youth, at diagnosis. Support teens as they transition to adult care teams and self-management.

Bottom line: balance tight control against hypoglycemia risk, match teaching to the child's cognitive development, and support the whole family. Good control in youth prevents early complications.

Special Considerations: Diabetes in Older Adults

Diabetes is common in older adults: nearly 1 in 3 Americans over 65 has it. Watch comorbidities, functional status, and elevated risks.

Individualized targets and hypoglycemia risk: Functionally well older adults may aim for A1C around 7.0-7.5%. Frail patients or those with multiple comorbidities are safer at higher targets (e.g., <8-8.5%). Hypoglycemia is especially dangerous here from fall risk, cognitive decline, and cardiovascular effects. Simplify regimens and avoid high-hypoglycemia-risk agents.

Functional and cognitive assessment: Some older adults manage complex regimens; others need support for vision, dexterity, or cognition. Assess ability and adjust care, using tools or caregiver help for monitoring and injections.

Medication safety: Avoid glyburide in the elderly (prolonged hypoglycemia). Metformin stays first-line but reassess as kidney function declines. Thiazolidinediones can worsen heart failure. SGLT2 inhibitors help cardiovascular risk but require monitoring for dehydration and infection. Simplify regimens to support adherence.

Comorbidities and complications: Hypertension, dyslipidemia, and neuropathy are common. Meet blood pressure and cholesterol targets cautiously. Routinely assess feet, fall risk, and vision; consider home safety checks.

Nutrition and social factors: Watch for malnutrition, reduced appetite, and financial barriers to food and medication. Coordinate with social services. Support adequate protein and calories while limiting hypoglycemia.

End-of-life care and de-intensification: With limited life expectancy, shift to comfort. Drop tight control; focus on avoiding symptomatic highs and preventing lows. Advocate for simplified regimens aligned with the patient's goals.

Bottom line: individualize and stay cautious. Avoid hypoglycemia and overly aggressive treatment, but control enough to prevent acute problems. Complicated regimens that cause anxiety can do more harm than good.

Nursing Management and Care Plans

Nurses run the day-to-day of diabetes care, from insulin drips in DKA to outpatient self-care teaching. Key assessments, diagnoses, interventions, and evaluation follow.

Nursing Assessment

Establish a baseline and find problems:

• Chief complaints and classic symptoms. Ask about polydipsia, polyuria, polyphagia, fatigue, unexplained weight changes, blurred vision, recurrent infections, and slow wound healing.
• Health history. Ask about first-degree relatives with diabetes; medications affecting glucose (corticosteroids, antipsychotics, immunosuppressants); diet, activity, alcohol, smoking, and recent weight change. In children, gather appetite, behavior, growth, and bedwetting from caregivers. In older adults, assess cognition, self-management ability, vision, dexterity, and home support. For known diabetics, identify type and date of diagnosis; review medications (names, doses, frequency, adherence); ask about home monitoring habits and typical readings; document the most recent HbA1c; and explore hypoglycemia history and barriers (cost, supply access, injection fear, lack of support).
• Physical exam. Vital signs: blood pressure (goal <130/80 mmHg for most), heart rate and respiratory rate (elevated in dehydration, infection, or DKA), temperature (infection), weight/BMI. Hydration: dry mucous membranes, poor turgor, sunken eyes suggest dehydration from hyperglycemia or DKA. Skin: check for dryness, bruising, fungal infection, slow-healing wounds, injection or pump sites for lipodystrophy, and the neck and axilla for acanthosis nigricans (insulin resistance). Eyes: ask about blurred vision or floaters; if trained, examine for retinopathy (microaneurysms, hemorrhages, cotton wool spots). Oral cavity: thrush, gum inflammation, dry mouth (xerostomia, which raises caries). Cardiovascular: palpate dorsalis pedis and posterior tibial pulses, auscultate carotids for bruits, and check for cold extremities, delayed capillary refill, or color change. Neurologic: test foot sensation with a 10g monofilament, vibration with a tuning fork, and ankle reflexes; ask about autonomic neuropathy (orthostatic dizziness, early satiety, resting tachycardia). Feet: remove shoes and socks; inspect for ulcers, calluses, deformity such as Charcot foot, fungal infection, dry skin, and nail or color/temperature change; palpate pedal pulses; check for loss of protective sensation. Injection sites (abdomen, thighs, arms): check for lipohypertrophy and rotate sites; inspect pump catheter sites for redness or infection.
• Labs. Review glucose records, HbA1c, lipid profile, renal function (creatinine, eGFR), and urine albumin. In hospitalized patients, track glucose trends and check electrolytes, especially potassium (insulin can cause hypokalemia by shifting potassium into cells).

Common Nursing Diagnoses

• Imbalanced Nutrition: Less than Body Requirements, from the inability to use glucose without insulin, shown by weight loss and muscle wasting (type 1 or poorly controlled). In overweight type 2, consider Imbalanced Nutrition: More than Body Requirements.
• Deficient Fluid Volume, from osmotic diuresis (DKA or severe hyperglycemia), shown by dehydration and high glucose.
• Risk for Unstable Blood Glucose Level, from limited knowledge and variable intake or adherence.
• Risk for Injury, from sensory alterations (peripheral neuropathy) and impaired circulation: foot injury, falls, or trauma from hypoglycemic confusion.
• Risk for Infection, from hyperglycemia and reduced circulation (UTI, skin/foot infection, poor wound healing).
• Impaired Skin Integrity, from reduced sensation and poor healing, possibly with a non-healing foot ulcer or pressure injury.
• Deficient Knowledge of diabetes management, from new diagnosis or lack of education on insulin, diet, monitoring, and complications.
• Ineffective Health Maintenance, from regimen complexity or psychosocial factors; identify the why (knowledge deficit, depression) rather than label noncompliance.
• Fatigue, from chronic hyperglycemia, when significant.
• Risk for Peripheral Neurovascular Dysfunction, with neuropathy or PAD.
• Anxiety or Fear, related to chronic disease, complications, or injections, common in newly diagnosed patients and families.

Planning: Goals and Outcomes

Set clear, measurable goals. The patient will:

• Maintain glucose in target range (e.g., 80-130 mg/dL fasting and <180 mg/dL postprandial, or individualized) without severe hypoglycemia.
• Demonstrate correct self-monitoring and medication technique and verbalize the regimen (dose, timing, side effects).
• Follow an appropriate meal plan and meet nutrition and weight goals.
• Keep skin and feet intact; existing wounds show healing.
• Avoid preventable complications (DKA, HHS, infections) and seek care promptly when very high or ill.
• With family, manage sick days, recognize highs and lows, and act appropriately.
• Engage in regular physical activity as tolerated.
• Attend followup appointments and screenings, including eyes and feet.
• Verbalize feelings about diabetes and use coping strategies or support resources when psychosocial issues exist.

Nursing Interventions and Implementation

1. Ensure adequate nutrition. Work with a dietitian on individualized plans; teach carbohydrate counting, portions, and meal timing. For insulin users, instruct on dose adjustment to carb intake (flexible regimens) or consistent carb intake (fixed dose). With undernutrition, push nutrient-dense, small frequent feedings and monitor intake. In NPO or hospitalized patients, advocate for insulin adjustment to prevent lows. For weight loss in type 2, set realistic goals (1-2 pounds/week) and practical strategies. Promote high-fiber foods and culturally appropriate substitutions; guide alcohol moderation paired with food.
2. Monitor and regulate glucose. Check per orders, typically before meals and at bedtime, or more often if NPO or unstable. Follow hypoglycemia protocols (15g fast-acting carbs, glucagon IM, IV dextrose) and document episodes. Recognize hyperglycemia and give insulin as ordered. Teach glucometer use, logkeeping, and when to test. Help CGM users interpret trends. Reinforce pattern management (morning highs may mean basal changes). Encourage hydration during hyperglycemia.
3. Administer medications safely. Verify insulin doses (double-check when needed) and give the correct type at the right time. Teach injection technique, site rotation, pen use, and mixing (clear before cloudy). Review oral schedules and side effects (GI upset with metformin, hypoglycemia with sulfonylureas). Address barriers with pillboxes, large-print labels, adaptive devices, or family support. Teach storage and never skipping basal insulin, even when ill. Connect patients to cost-assistance resources.
4. Skin and foot care. Teach daily foot inspection (mirror or caregiver), proper hygiene (wash, dry between toes, moisturize), supportive closed-toe shoes, and no barefoot walking. Refer to podiatry for nail care or deformities. Advise testing water temperature and avoiding heating pads with neuropathy. Treat minor injuries promptly and teach when to seek care. Inpatient: assess feet, document wounds, and consult wound care or podiatry.
5. Prevent infection. Reinforce vaccination (influenza, pneumonia, hepatitis B, COVID-19), good oral and skin hygiene, and sick-day guidelines (continue meds, increase monitoring, hydrate, check ketones in type 1). Watch for infection and treat promptly (cultures, antibiotics). Educate on steroid-related hyperglycemia and use sterile technique with devices.
6. Promote physical activity. Assess baseline and recommend safe options (walking, cycling, swimming). Teach checking glucose before activity and carrying carbohydrates. Postpone exercise if a type 1 patient has >250 mg/dL and positive ketones. Personalize for older or limited-mobility patients (chair exercises) and document the plan.
7. Patient education. Explain type 1 versus type 2 in plain terms; reinforce medications and hypo/hyperglycemia signs and treatment; train on pens, CGMs, and pumps; cover foot care, BP and cholesterol management, and followup labs. Use teach-back ("What would you do if your sugar drops to 60?") and provide materials, support groups, and educators.
8. Safety and emergency preparedness. Recommend medical ID bracelets for insulin users, carrying glucose at all times (especially when driving), home safety checks for vision or neuropathy deficits, and teaching caregivers to give glucagon.
9. Psychosocial support. Normalize emotional responses, watch for depression or anxiety and refer, involve family, and connect patients to peer support or counseling.
10. Collaborative care. Work with dietitians, diabetes educators, endocrinologists, and podiatrists; coordinate referrals for pregnancy planning, advanced complications, or psychosocial needs; and provide clear discharge planning with instructions, prescriptions, and followup.

Evaluation

Evaluate against the care-plan goals:

• Glucose control. Is the patient holding fasting and postprandial glucose in range with fewer highs and lows? Review SMBG logs or CGM data, and for inpatients whether fingersticks have stabilized. A good long-term sign is an improving HbA1c (for example, a drop from 9.5% to 7.2% after three months). If targets are missed, ask whether the regimen needs adjusting, adherence is the issue, or goals are unrealistic.
• Knowledge and self-management. Can the patient demonstrate insulin administration, state the schedule, and verbalize sick-day rules and actions for highs and lows? Confirm with teach-back.
• Lifestyle adherence. Is the patient following diet and activity recommendations, shown by behavior change and appropriate weight change (for example, losing 5 lbs in a month in type 2 or regaining weight after DKA in type 1)?
• Complication prevention. Free of new foot ulcers or infections, with existing wounds healing? Attending eye and foot appointments? Kidney function stable or improved (no new microalbuminuria)?
• Emotional well-being. Less anxious and more confident? Improving PHQ-9 scores or increased participation suggest progress.
• Followup engagement. Attending appointments, bringing logs, and asking informed questions.

If goals are not met, reassess and revise. Persistent hyperglycemia may need medication or dietary changes; technique problems may need a home health nurse or diabetes educator. Diabetes management is dynamic, so evaluate and adjust continuously.

Documentation

Document all teaching and the patient's response, glucose patterns, hypoglycemia treatment, and progress toward goals. Good documentation supports continuity of care and quality improvement.

With a comprehensive plan, the expected outcomes are stable glucose, minimal complications, and good quality of life. Effective nursing care puts patients in control of their diabetes rather than the reverse.

Frequently Asked Questions

What is the difference between type 1 and type 2 diabetes? Type 1 is an autoimmune destruction of the insulin-producing beta cells, leaving an absolute insulin deficiency that requires lifelong insulin. Type 2, which is over 90% of cases, combines insulin resistance with a relative insulin deficiency and usually starts with lifestyle change and oral agents (CDC).

How common is diabetes? The International Diabetes Federation estimates 589 million adults worldwide were living with diabetes in 2024, roughly 1 in 9, projected to reach 853 million by 2050. In the United States, about 38.4 million people (11.6%) have diabetes (CDC, IDF).

How is diabetes diagnosed? Standard criteria are a fasting plasma glucose of 126 mg/dL or higher, a 2-hour OGTT of 200 mg/dL or higher, an A1C of 6.5% or higher, or a random glucose of 200 mg/dL or higher with classic symptoms. Prediabetes sits just below these cutoffs (ADA).

What are the acute emergencies a nurse must catch? Hypoglycemia (treat fast with carbohydrate or glucagon), diabetic ketoacidosis (DKA), and hyperosmolar hyperglycemic state (HHS). Each can be fatal, so early recognition and prompt treatment matter more than anything else at the bedside.

Can type 2 diabetes be prevented or reversed? Prediabetes can often be delayed or reversed with weight loss, healthy eating, and regular activity. Type 2 can sometimes be put into remission with sustained lifestyle change and weight loss, though it is managed, not cured. Type 1 cannot be prevented (CDC).

What does the nurse teach for long-term complication prevention? Glucose monitoring, medication and insulin technique, foot and skin care, blood pressure and cholesterol control, vaccination, sick-day rules, and keeping eye, foot, and kidney follow-up appointments. Most of the nurse's impact is education and pattern recognition (ADA).